Always Evolving and Adapting

FINRA, OTC Markets and Market Maker Support in an OTC Markets Listing

Strategic legal guidance on FINRA Rule 15c2-11 compliance, ticker assignment, and OTC market-maker support. Anthony, Linder & Cacomanolis provides expert analysis on Form 211 filings and secondary market liquidity.

FINRA, OTC, and Market-Maker Considerations: The Infrastructure of Secondary Trading

For issuers that do not yet meet the initial listing requirements of a national exchange, or those transitioning from a public shell through a reverse merger, the over-the-counter (OTC) markets provide a vital venue for liquidity. However, the path to a trading ticker is not direct; it is governed by FINRA as the primary gatekeeper and regulated by the SEC’s “gatekeeper” rule for broker-dealers. Anthony, Linder & Cacomanolis provides sophisticated counsel to issuers, facilitating the complex interplay between 15c2-11 compliance, market-maker sponsorship, and the FINRA corporate action process.

Rule 15c2-11: The Gateway to Public Quotations

SEC Rule 15c2-11 is the foundational regulation governing the “publication of quotations” for securities not listed on a national exchange. Under this rule, a market maker cannot initiate or resume a quote for a security unless it has performed a rigorous review of the issuer’s “current public information.”

The 2021 Amendments and the End of “Gray Market” Languishing

Prior to 2021, many issuers remained “dark” while their stock continued to trade. The SEC’s amended Rule 15c2-11 now requires that an issuer’s financial and operational information be “current and publicly available” for its securities to remain quoted on the OTC Pink or higher tiers.

Publicly Available Requirement: Information must be available on EDGAR or a publicly accessible website.
The “Piggyback” Exemption: Once a market maker has established a quote by filing a Form 211, other market makers can “piggyback” on that quote without a separate filing, provided the issuer remains current in its reporting.

The Form 211 Process and Market-Maker Sponsorship

An issuer cannot file with FINRA to receive a ticker symbol directly; it must be sponsored by a registered broker-dealer acting as a market maker.

The Role of the Sponsoring Market Maker

The market maker serves as a regulatory intermediary. Before submitting a Form 211 to FINRA, the market maker must conduct a due diligence review of the issuer, including:

Issuer Background: Corporate history, business operations, and the identity of all 10% owners and control persons.
Financial Integrity: Review of audited (for SEC reporting companies) or reviewed financial statements.
Issuance History: A detailed log of all shares issued in the preceding three years to ensure there are no “illegal distributions” of unregistered stock.

FINRA Review and Deficiency Letters

Once the Form 211 is submitted, FINRA’s Department of Market Regulation reviews the filing to ensure compliance with Rule 15c2-11.

Standard of Review: FINRA does not “approve” the company; it determines if the market maker has a “reasonable basis” for believing the information is accurate and from a reliable source.
Timelines: The review process typically takes 4 to 8 weeks but can be extended if FINRA issues “deficiency letters” requesting clarification on the issuer’s shell status, shareholder base, or the validity of specific private placements.

Ticker Assignment and Corporate Actions

The assignment of a four- or five-letter ticker symbol is the final step in the OTC listing process.

Symbol Selection

While FINRA ultimately assigns the ticker, issuers can request specific symbols. We assist clients in coordinating with the FINRA Department of Corporate Actions (DCA) to reserve symbols that align with their branding, provided the symbol is not already in use or reserved by another issuer.

Rule 10b-17 and Notice Requirements

For existing OTC companies, any “corporate action”—such as a name change, a forward/reverse stock split, or a spin-off—requires a notification to FINRA at least 10 calendar days prior to the record date of the action.

Form 10b-17 Compliance: Failure to provide timely notice can result in significant market disruption, trading halts, or the assessment of “Daily Record” processing fees by FINRA.
The “U” Ticker Suffix: If an issuer fails to file its periodic reports (10-K or 10-Q) in a timely manner, FINRA may append a “U” to the ticker symbol to signal to the market that the issuer is “Unreliable” or delinquent in its reporting.

Coordinating Market-Maker Support and Liquidity

A ticker symbol without active market-maker support results in a “thin” market with wide bid-ask spreads. Anthony, Linder & Cacomanolis provides strategic guidance on:

Selecting Sponsoring Market Makers: Identifying broker-dealers that specialize in the issuer’s specific sector or market cap.
DTC Eligibility: Facilitating the process with the Depository Trust Company (DTC) to ensure shares can be cleared and settled electronically, a prerequisite for most institutional and retail broker-dealers to allow trading.
Blue Sky Compliance: Managing the state-level registration or exemption process to allow market makers to solicit trades in specific jurisdictions.

Authority Through Professional Experience

Our firm’s expertise in the mechanics of the OTC markets is grounded in a deep history of representing issuers and broker-dealers before FINRA. We invite executive leadership to explore our extensive library of insights at our corporate website and our specialized blog site, www.securitieslawblog.com, for detailed discussions on the 2021 amendments to Rule 15c2-11 and the impact of the “shell company” designation on ticker eligibility.

Schedule an Executive Strategy Consultation

Navigating the transition to a quoted OTC security requires an authoritative partner who understands the intersection of market-maker due diligence and FINRA regulation. Anthony, Linder & Cacomanolis invites you to engage in a high-level strategy consultation to evaluate your OTC listing roadmap.

Schedule an executive strategy consultation with our senior partners to discuss your FINRA and OTC needs by calling 877-541-3263 or visiting our contact page.